The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates.
 
Tom Wei-Wu Chen
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Roche
Research Funding - Eisai; Epizyme
Travel, Accommodations, Expenses - Eisai; Roche
 
Chueh-Chuan Yen
Honoraria - CStone Pharmaceuticals; Daiichi Sankyo; Deciphera; TTY Biopharm
Consulting or Advisory Role - CStone Pharmaceuticals; Daiichi Sankyo; Deciphera
Research Funding - Athenex (Inst); BioAtla; Deciphera (Inst); Efficient Pharma Management Corp. (Inst); Eisai (Inst); Ono Pharmaceutical (Inst); Taiwan Liposome (Inst)
 
Ruey-Long Hong
No Relationships to Disclose
 
Jen-Chieh Lee
No Relationships to Disclose
 
Koping Chang
No Relationships to Disclose
 
Chih-Wei Yu
No Relationships to Disclose
 
San-Chi Chen
Speakers' Bureau - Eisai
 
Mei-Lu Chen
No Relationships to Disclose
 
Meng-Chi Hsu
No Relationships to Disclose
 
Ting-Fang Kung
No Relationships to Disclose
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche